sr141716 has been researched along with Diabetes Mellitus in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CP; Chao, YS; Chou, MC; Chu, CM; Chung, WL; Hsieh, MT; Hsieh, WP; Hung, MS; Jan, JJ; Kuo, CW; Lin, CY; Lin, Y; Shia, KS; Shy, HS; Song, JS; Tseng, SL; Wu, CH; Yeh, TK; Yeh, YN | 1 |
| Azzarone, B; Beaudreuil, S; Charpentier, B; Chatziantoniou, C; Dalia, M; Desterke, C; Devocelle, A; Durrbach, A; Ferlicot, S; François, H; Giron-Michel, J; Grassin-Delyle, S; Ivanovski, N; Lecru, L; Ledent, C; Saïd, M; Vandermeersch, S; Vazquez, A; Vernochet, A | 1 |
| Kautzky-Willer, A; Lemmens-Gruber, R | 1 |
| Wadman, M | 1 |
| Esposito, K; Giugliano, D | 1 |
| Bray, G; Hadley, RD; Henry, RR; Lillo, JL; Woods, SC | 1 |
| Ahmed, MH | 1 |
| Bloch, MJ; Bronander, KA | 1 |
| Saavedra, LE | 1 |
| Berry, C; Bourassa, MG | 1 |
3 review(s) available for sr141716 and Diabetes Mellitus
| Article | Year |
|---|---|
Obesity and diabetes.
Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Sex Characteristics; Sulfonylurea Compounds | 2012 |
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome | 2007 |
Endocannabinoid system and cardiometabolic risk.
Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
8 other study(ies) available for sr141716 and Diabetes Mellitus
| Article | Year |
|---|---|
Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesi
Topics: Animals; Anti-Obesity Agents; Cell Line; Diabetes Mellitus; Diet; Drug Discovery; Drug Inverse Agonism; Eating; Humans; Imidazoles; Inhibitory Concentration 50; Male; Mice; Mice, Obese; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substrate Specificity; Thiones | 2009 |
Cannabinoid receptor 1 is a major mediator of renal fibrosis.
Topics: Acute Disease; Animals; Arachidonic Acids; Cells, Cultured; Chemokine CCL2; Collagen; Diabetes Mellitus; Disease Models, Animal; Endocannabinoids; Fibrosis; Gene Expression Profiling; Glomerulonephritis, IGA; Glycerides; Humans; Kidney; Ligands; Macrophages; Mice; Mice, Knockout; Myofibroblasts; Nephritis, Interstitial; Oligonucleotide Array Sequence Analysis; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; RNA, Messenger; Transforming Growth Factor beta1; Up-Regulation; Ureteral Obstruction | 2015 |
[In diabetes cannabinoid antagonist kills two birds with one stone].
Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Controlled Clinical Trials as Topic; Diabetes Mellitus; Glycated Hemoglobin; Humans; Metabolic Syndrome; Piperidines; Placebos; Pyrazoles; Rimonabant; Time Factors; Weight Loss | 2005 |
Appetite downer awaits approval.
Topics: Appetite; Appetite Depressants; Clinical Trials as Topic; Diabetes Mellitus; Drug Approval; Drug Industry; Europe; France; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss | 2005 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
Cardiometabolic risk modification: current trends and emerging therapies.
Topics: Adipose Tissue; Antihypertensive Agents; Appetite; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Obesity; Physician Assistants; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors; Weight Gain | 2006 |
Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention.
Topics: Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus; Humans; Metabolic Syndrome; Middle East; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Saudi Arabia | 2007 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss | 2008 |